Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies

J Invest Dermatol. 2015 Jul;135(7):1705-1707. doi: 10.1038/jid.2015.149.

Authors

David T Woodley¹, Mei Chen²

Affiliations

¹ Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Electronic address: dwoodley@med.usc.edu.
² Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

PMID: 26066885
DOI: 10.1038/jid.2015.149

No abstract available

Publication types

Editorial
Review

MeSH terms

Allografts
Animals
Anti-Bacterial Agents / therapeutic use
Cohort Studies
Collagen Type VII / genetics*
Disease Models, Animal
Epidermolysis Bullosa Dystrophica / diagnosis
Epidermolysis Bullosa Dystrophica / genetics*
Epidermolysis Bullosa Dystrophica / therapy*
Female
Genes, Recessive / genetics*
Genetic Predisposition to Disease*
Genetic Therapy / methods*
Hematopoietic Stem Cell Transplantation / methods
Humans
Laboratories
Male
Mice
Mutation
Prognosis
Rare Diseases
Risk Assessment
Severity of Illness Index
Treatment Outcome

Substances

Anti-Bacterial Agents
COL7A1 protein, human
Collagen Type VII